1436 related articles for article (PubMed ID: 12688351)
21. De novo mast cell leukemia without CD25 expression and KIT mutations: a rare case report in a 13-year-old child.
Zheng Y; Nong L; Liang L; Wang W; Li T
Diagn Pathol; 2018 Feb; 13(1):14. PubMed ID: 29458385
[TBL] [Abstract][Full Text] [Related]
22. The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markers.
Horny HP; Sotlar K; Stellmacher F; Krokowski M; Agis H; Schwartz LB; Valent P
J Clin Pathol; 2006 Mar; 59(3):298-302. PubMed ID: 16505282
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L).
Jordan JH; Walchshofer S; Jurecka W; Mosberger I; Sperr WR; Wolff K; Chott A; Bühring HJ; Lechner K; Horny HP; Valent P
Hum Pathol; 2001 May; 32(5):545-52. PubMed ID: 11381374
[TBL] [Abstract][Full Text] [Related]
24. Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia.
Sotlar K; Marafioti T; Griesser H; Theil J; Aepinus C; Jaussi R; Stein H; Valent P; Horny HP
Mol Pathol; 2000 Aug; 53(4):188-93. PubMed ID: 11040941
[TBL] [Abstract][Full Text] [Related]
25. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340
[TBL] [Abstract][Full Text] [Related]
26. Update on Mastocytosis (Part 2): Categories, Prognosis, and Treatment.
Azaña JM; Torrelo A; Matito A
Actas Dermosifiliogr; 2016; 107(1):15-22. PubMed ID: 26525106
[TBL] [Abstract][Full Text] [Related]
27. Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998.
Valent P; Escribano L; Parwaresch RM; Schemmel V; Schwartz LB; Sotlar K; Sperr WR; Horny HP
Int Arch Allergy Immunol; 1999 Sep; 120(1):1-7. PubMed ID: 10529583
[TBL] [Abstract][Full Text] [Related]
28. Mastocytosis and related entities: a practical roadmap.
Beyens M; Elst J; van der Poorten ML; Van Gasse A; Toscano A; Verlinden A; Vermeulen K; Maes MB; Oude Elberink JNGH; Ebo D; Sabato V
Acta Clin Belg; 2023 Aug; 78(4):325-335. PubMed ID: 36259506
[TBL] [Abstract][Full Text] [Related]
29. Mastocytosis: a comprehensive insight.
VAN Gysel D; DE Maeseneer H; Oranje AP
G Ital Dermatol Venereol; 2016 Aug; 151(4):385-96. PubMed ID: 27070304
[TBL] [Abstract][Full Text] [Related]
30. Mastocytosis in children: a single-center long-term follow-up study.
Popadic S; Lalosevic J; Lekic B; Gajić-Veljic M; Bonaci-Nikolic B; Nikolic M
Int J Dermatol; 2023 May; 62(5):616-620. PubMed ID: 36807903
[TBL] [Abstract][Full Text] [Related]
31. Acute myeloid leukaemia with t(8;21) associated with "occult" mastocytosis. Report of an unusual case and review of the literature.
Bernd HW; Sotlar K; Lorenzen J; Osieka R; Fabry U; Valent P; Horny HP
J Clin Pathol; 2004 Mar; 57(3):324-8. PubMed ID: 14990611
[TBL] [Abstract][Full Text] [Related]
32. Expression of CD2 and CD25 on mast cell populations can be seen outside the setting of systemic mastocytosis.
Cherian S; McCullouch V; Miller V; Dougherty K; Fromm JR; Wood BL
Cytometry B Clin Cytom; 2016 Jul; 90(4):387-92. PubMed ID: 26525770
[TBL] [Abstract][Full Text] [Related]
33. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.
Teodosio C; García-Montero AC; Jara-Acevedo M; Alvarez-Twose I; Sánchez-Muñoz L; Almeida J; Morgado JM; Matito A; Escribano L; Orfao A
Leukemia; 2012 May; 26(5):951-8. PubMed ID: 22051531
[TBL] [Abstract][Full Text] [Related]
34. [Clinical observations in cutan mastocytosis].
Mihalik N; Hidvégi B; Hársing J; Várkonyi J; Csomor J; Kovalszky I; Marschalkó M; Kárpáti S
Orv Hetil; 2013 Sep; 154(37):1469-75. PubMed ID: 24016753
[TBL] [Abstract][Full Text] [Related]
35. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.
Longley BJ; Tyrrell L; Lu SZ; Ma YS; Langley K; Ding TG; Duffy T; Jacobs P; Tang LH; Modlin I
Nat Genet; 1996 Mar; 12(3):312-4. PubMed ID: 8589724
[TBL] [Abstract][Full Text] [Related]
36. Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment.
Akin C; Valent P; Escribano L
Curr Allergy Asthma Rep; 2006 Jul; 6(4):282-8. PubMed ID: 16822380
[TBL] [Abstract][Full Text] [Related]
37. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2021 Apr; 96(4):508-525. PubMed ID: 33524167
[TBL] [Abstract][Full Text] [Related]
38. Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow.
Johnson MR; Verstovsek S; Jorgensen JL; Manshouri T; Luthra R; Jones DM; Bueso-Ramos CE; Medeiros LJ; Huh YO
Mod Pathol; 2009 Jan; 22(1):50-7. PubMed ID: 19116630
[TBL] [Abstract][Full Text] [Related]
39. Controversies in Allergy: Is a Bone Marrow Biopsy Optional or Essential in the Evaluation of the Patient with a Suspected Mast Cell Disorder?
Greenberger PA; Metcalfe DD
J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1134-1138. PubMed ID: 30630762
[No Abstract] [Full Text] [Related]
40. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2015 Mar; 90(3):250-62. PubMed ID: 25688753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
